Syed Atiqul Haq
Research Subjects
Research Interests
Syed Atiqul Haq has a total of 189 co-authors. Here are the top co-authors by number of shared publications:
- Johannes Jacobus Rasker
Faculty of Behavioral, Management and Social Sciences, Department Psychology, Health and Technology, University of Twente, Enschede, The Netherlands
7 shared publications - Minhaj Rahim Choudhury
Department of Rheumatology Bangladesh Medical University Dhaka Bangladesh
6 shared publications - Mohammad Mostafa Zaman
Department of Public Health and Informatics, Bangladesh Medical University, Dhaka, Bangladesh
5 shared publications - Nahiduzzamane Shazzad
Rheumatology, Bangladesh Medical University, Dhaka, BGD
5 shared publications - Shamim Ahmed
Faculty of Medicine Bangladesh Medical University Dhaka Bangladesh
5 shared publications Abu Shahin
Department of Rheumatology Bangabandhu Sheikh Mujib Medical University Dhaka Bangladesh
3 shared publications
Latest Publications
- 15 April 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
Prevalence of Comorbidities and Poor Prognostic Factors Among Patients With Rheumatoid Arthritis in Bangladesh
Objective: This study aimed to assess the prevalence of comorbidities among patients with rheumatoid arthritis (RA) and identify factors associated with it. Methods: A cross-sectional study was conducted at 2 tertiary care hospitals among 653 patients with RA. Data on demographics, poor prognostic factors (high erythrocyte sedimentation rate [ESR], C-reactive protein [CRP], rheumatoid factor, anticyclic citrullinated peptide antibody titers, and Disease Activity Score in 28 joints [DAS28] > 5.1), and comorbidities were collected through a structured questionnaire and medical record review. Comorbidities were quantified by the Charlson Comorbidity Index (CCI). Logistic regression analyses were used to identify associated factors. Results: A total of 646 (98.9%) patients had ≥ 1 comorbidity. The most prevalent were dyslipidemia (75.8%), obesity (58.7%), hypertension (42.7%), type 2 diabetes mellitus (30.3%), and osteoporosis (OP; 15.6%). Age ≥ 45 years was independently associated with coronary artery disease (odds ratio [OR] 9.71, 95% CI 1.91-178.00), OP (OR 19.60, 95% CI 5.96-121.00) and infectious diseases (OR 1.60, 95% CI 1.03-2.54). Female sex was associated with lower cardiovascular risk (OR 0.27, 95% CI 0.11-0.62), whereas female sex was associated with increased odds of OP (OR 3.55, 95% CI 1.71-8.37) and gastrointestinal (GI) disorders (OR 2.18, 95% CI 1.37-3.56). The use of targeted synthetic and biologic disease-modifying antirheumatic drugs increased the risk of infection (OR 14.80 and 4.11, respectively). High DAS28-CRP and ESR values were linked to GI comorbidities. The CCI survival index was significantly lower in older patients (≥ 45 years; mean 68.7 [SD 26.7]) than in younger patients (mean 93.3 [SD 6.7], P < 0.001). Conclusion: The prevalence of multimorbidity is high among patients with RA in Bangladesh, particularly early cardiovascular disease risk.
- 15 April 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
Prevalence of Comorbidities and Poor Prognostic Factors Among Patients With Rheumatoid Arthritis in Bangladesh
Objective: This study aimed to assess the prevalence of comorbidities among patients with rheumatoid arthritis (RA) and identify factors associated with it. Methods: A cross-sectional study was conducted at 2 tertiary care hospitals among 653 patients with RA. Data on demographics, poor prognostic factors (high erythrocyte sedimentation rate [ESR], C-reactive protein [CRP], rheumatoid factor, anticyclic citrullinated peptide antibody titers, and Disease Activity Score in 28 joints [DAS28] > 5.1), and comorbidities were collected through a structured questionnaire and medical record review. Comorbidities were quantified by the Charlson Comorbidity Index (CCI). Logistic regression analyses were used to identify associated factors. Results: A total of 646 (98.9%) patients had ≥ 1 comorbidity. The most prevalent were dyslipidemia (75.8%), obesity (58.7%), hypertension (42.7%), type 2 diabetes mellitus (30.3%), and osteoporosis (OP; 15.6%). Age ≥ 45 years was independently associated with coronary artery disease (odds ratio [OR] 9.71, 95% CI 1.91-178.00), OP (OR 19.60, 95% CI 5.96-121.00) and infectious diseases (OR 1.60, 95% CI 1.03-2.54). Female sex was associated with lower cardiovascular risk (OR 0.27, 95% CI 0.11-0.62), whereas female sex was associated with increased odds of OP (OR 3.55, 95% CI 1.71-8.37) and gastrointestinal (GI) disorders (OR 2.18, 95% CI 1.37-3.56). The use of targeted synthetic and biologic disease-modifying antirheumatic drugs increased the risk of infection (OR 14.80 and 4.11, respectively). High DAS28-CRP and ESR values were linked to GI comorbidities. The CCI survival index was significantly lower in older patients (≥ 45 years; mean 68.7 [SD 26.7]) than in younger patients (mean 93.3 [SD 6.7], P < 0.001). Conclusion: The prevalence of multimorbidity is high among patients with RA in Bangladesh, particularly early cardiovascular disease risk.
- 28 October 2024
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 27 (11) , e15380
In memoriam: Professor Debashish Danda, MBBS, MD, DM, FRCP
- 28 October 2024
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 27 (11) , e15380
In memoriam: Professor Debashish Danda, MBBS, MD, DM, FRCP
- Open Access
- 2 November 2023
- Published by BMJ in BMJ Global Health
- Vol. 8 (11) , e013786
‘It’s about time’. Dissemination and evaluation of a global health systems strengthening roadmap for musculoskeletal health – insights and future directions
Actions towards the health-related Sustainable Development Goal 3.4 typically focus on non-communicable diseases (NCDs) associated with premature mortality, with less emphasis on NCDs associated with disability, such as musculoskeletal conditions—the leading contributor to the global burden of disability. Can systems strengthening priorities for an underprioritised NCD be codesigned, disseminated and evaluated? A ‘roadmap’ for strengthening global health systems for improved musculoskeletal health was launched in 2021. In this practice paper, we outline dissemination efforts for this Roadmap and insights on evaluating its reach, user experience and early adoption. A global network of 22 dissemination partners was established to drive dissemination efforts, focussing on Africa, Asia and Latin America, each supported with a suite of dissemination assets. Within a 6-month evaluation window, 52 Twitter posts were distributed, 2195 visitors from 109 countries accessed the online multilingual Roadmap and 138 downloads of the Roadmap per month were recorded. Among 254 end users who answered a user-experience survey, respondents ‘agreed’ or ‘strongly agreed’ the Roadmap was valuable (88.3%), credible (91.2%), useful (90.1%) and usable (85.4%). Most (77.8%) agreed or strongly agreed they would adopt the Roadmap in some way. Collection of real-world adoption case studies allowed unique insights into adoption practices in different contexts, settings and health system levels. Diversity in adoption examples suggests that the Roadmap has value and adoption potential at multiple touchpoints within health systems globally. With resourcing, harnessing an engaged global community and establishing a global network of partners, a systems strengthening tool can be cocreated, disseminated and formatively evaluated.
- 2 November 2023
- Published by BMJ in BMJ Global Health
- Vol. 8 (11) , e013786
Open Access‘It’s about time’. Dissemination and evaluation of a global health systems strengthening roadmap for musculoskeletal health – insights and future directions
Actions towards the health-related Sustainable Development Goal 3.4 typically focus on non-communicable diseases (NCDs) associated with premature mortality, with less emphasis on NCDs associated with disability, such as musculoskeletal conditions—the leading contributor to the global burden of disability. Can systems strengthening priorities for an underprioritised NCD be codesigned, disseminated and evaluated? A ‘roadmap’ for strengthening global health systems for improved musculoskeletal health was launched in 2021. In this practice paper, we outline dissemination efforts for this Roadmap and insights on evaluating its reach, user experience and early adoption. A global network of 22 dissemination partners was established to drive dissemination efforts, focussing on Africa, Asia and Latin America, each supported with a suite of dissemination assets. Within a 6-month evaluation window, 52 Twitter posts were distributed, 2195 visitors from 109 countries accessed the online multilingual Roadmap and 138 downloads of the Roadmap per month were recorded. Among 254 end users who answered a user-experience survey, respondents ‘agreed’ or ‘strongly agreed’ the Roadmap was valuable (88.3%), credible (91.2%), useful (90.1%) and usable (85.4%). Most (77.8%) agreed or strongly agreed they would adopt the Roadmap in some way. Collection of real-world adoption case studies allowed unique insights into adoption practices in different contexts, settings and health system levels. Diversity in adoption examples suggests that the Roadmap has value and adoption potential at multiple touchpoints within health systems globally. With resourcing, harnessing an engaged global community and establishing a global network of partners, a systems strengthening tool can be cocreated, disseminated and formatively evaluated.
- Open Access
Pachydermoperiostosis Mimicking Inflammatory Arthritis: Case Description and Narrative Review
Pachydermoperiostosis (PDP), also called primary hypertrophic osteoarthropathy (HOA), is a rare genetic disease with typical thickening of the skin (pachydermia) and rheumatic manifestations, with clubbing of the fingers and toes and periostosis of the long bones visible on X-rays, as well as arthritis in large joints sometimes. Case: We describe a 23-year-old man with a complete form of PDP who presented with polyarthritis of the ankles and knees, with clubbing of the fingers and toes. He was treated with a non-steroidal anti-inflammatory drug (NSAID), etoricoxib, and with bisphosphonates (initially pamidronic acid i.v. and later oral risedronate 35 mg weekly). His joint pains and swelling disappeared, so that he could resume his daily activities. After eight years, the periostosis on the X-rays had disappeared. Discussion: The case is discussed, the literature regarding PDP is summarized and the differential diagnosis and treatment options are reviewed. Conclusions: PDP may present as polyarthritis. Clinicians should be aware of this diagnosis, as treatment is available and may improve the outcome of the patient. It is important to rule out secondary HOA due to pulmonary or cardiac disease, gastrointestinal malignancies and liver cirrhosis, especially when the dermatological findings are not typical. Further, acromegaly, thyroid acropachy and rheumatologic diseases should be excluded.
Open AccessPachydermoperiostosis Mimicking Inflammatory Arthritis: Case Description and Narrative Review
Pachydermoperiostosis (PDP), also called primary hypertrophic osteoarthropathy (HOA), is a rare genetic disease with typical thickening of the skin (pachydermia) and rheumatic manifestations, with clubbing of the fingers and toes and periostosis of the long bones visible on X-rays, as well as arthritis in large joints sometimes. Case: We describe a 23-year-old man with a complete form of PDP who presented with polyarthritis of the ankles and knees, with clubbing of the fingers and toes. He was treated with a non-steroidal anti-inflammatory drug (NSAID), etoricoxib, and with bisphosphonates (initially pamidronic acid i.v. and later oral risedronate 35 mg weekly). His joint pains and swelling disappeared, so that he could resume his daily activities. After eight years, the periostosis on the X-rays had disappeared. Discussion: The case is discussed, the literature regarding PDP is summarized and the differential diagnosis and treatment options are reviewed. Conclusions: PDP may present as polyarthritis. Clinicians should be aware of this diagnosis, as treatment is available and may improve the outcome of the patient. It is important to rule out secondary HOA due to pulmonary or cardiac disease, gastrointestinal malignancies and liver cirrhosis, especially when the dermatological findings are not typical. Further, acromegaly, thyroid acropachy and rheumatologic diseases should be excluded.
- Open Access
- 1 March 2023
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 17 (1) , 1-6
Tofacitinib for the treatment of inflammatory bowel disease-associated arthritis: two case reports
Background: Musculoskeletal manifestations are common extraintestinal manifestations of inflammatory bowel disease. Tofacitinib is a Janus kinase inhibitor approved for treating rheumatoid arthritis and ulcerative colitis. There are limited data on the efficacy of tofacitinib in managing inflammatory bowel disease-associated arthritis. Here we report two patients with ulcerative colitis- and Crohn’s disease-associated arthritis successfully responding to tofacitinib. Cases: A 34-year-old Bangladeshi woman presented with lower limb polyarthritis for 7 years. Six months after the onset of polyarthritis, she developed abdominal pain with rectal bleeding. Colonoscopy and rectal biopsy findings confirmed ulcerative colitis. Ulcerative colitis associated arthritis was diagnosed. Treatment with sulfasalazine, etanercept, adalimumab, infliximab, and methotrexate gave no long-lasting remission. Methotrexate with mesalazine gave a partial response, and tofacitinib 5 mg twice per day was added. Her articular and abdominal symptoms improved within a month, and remission persisted till 24 months of follow-up, except a short-lasting mild flare at the seventh month. A 52-year-old Bangladeshi man had Crohn’s disease for 5 years. He presented with a swollen left knee and pain in other joints. Laboratory showed positive HLA-B27. He was intolerant to sulfasalazine and experienced poor response to methotrexate. Due to his inability to afford anti-tumor necrosis factor, tofacitinib was initiated. His arthritis improved within a month, and he remained in remission up to the sixth month. Conclusions: In a woman with ulcerative colitis associated arthritis, refractory to biologic therapy, both arthritis and colitis improved with tofacitinib. A patient with Crohn’s disease-associated arthritis went into remission with tofacitinib. Tofacitinib may be effective in inflammatory bowel disease-associated arthritis.
- 1 March 2023
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 17 (1) , 1-6
Open AccessTofacitinib for the treatment of inflammatory bowel disease-associated arthritis: two case reports
Background: Musculoskeletal manifestations are common extraintestinal manifestations of inflammatory bowel disease. Tofacitinib is a Janus kinase inhibitor approved for treating rheumatoid arthritis and ulcerative colitis. There are limited data on the efficacy of tofacitinib in managing inflammatory bowel disease-associated arthritis. Here we report two patients with ulcerative colitis- and Crohn’s disease-associated arthritis successfully responding to tofacitinib. Cases: A 34-year-old Bangladeshi woman presented with lower limb polyarthritis for 7 years. Six months after the onset of polyarthritis, she developed abdominal pain with rectal bleeding. Colonoscopy and rectal biopsy findings confirmed ulcerative colitis. Ulcerative colitis associated arthritis was diagnosed. Treatment with sulfasalazine, etanercept, adalimumab, infliximab, and methotrexate gave no long-lasting remission. Methotrexate with mesalazine gave a partial response, and tofacitinib 5 mg twice per day was added. Her articular and abdominal symptoms improved within a month, and remission persisted till 24 months of follow-up, except a short-lasting mild flare at the seventh month. A 52-year-old Bangladeshi man had Crohn’s disease for 5 years. He presented with a swollen left knee and pain in other joints. Laboratory showed positive HLA-B27. He was intolerant to sulfasalazine and experienced poor response to methotrexate. Due to his inability to afford anti-tumor necrosis factor, tofacitinib was initiated. His arthritis improved within a month, and he remained in remission up to the sixth month. Conclusions: In a woman with ulcerative colitis associated arthritis, refractory to biologic therapy, both arthritis and colitis improved with tofacitinib. A patient with Crohn’s disease-associated arthritis went into remission with tofacitinib. Tofacitinib may be effective in inflammatory bowel disease-associated arthritis.
- Open Access
- 24 February 2023
- Published by Wiley in Rheumatology & Autoimmunity
- Vol. 3 (1) , 43-49
HLA‐DQ and ‐DR alleles in patients with SLE: A tertiary hospital‐based case–control study in Bangladesh
Background: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the involvement of multiple organs and autoantibody production. This study aimed to determine the association of human leukocyte antigen (HLA)‐DQ and ‐DR alleles with SLE at a tertiary hospital in Bangladesh.Methods: This case–control study was conducted in the Department of Rheumatology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh. The patients who fulfilled the 1997 revised American College of Rheumatology classification criteria for SLE were considered cases (n = 41). The controls (n = 32) were selected from the hospital staff of BSMMU, including doctors and nurses who did not suffer from any known rheumatic diseases, and there was no such disease in their first‐degree relatives. Polymerase chain reaction using a sequence‐specific primer (PCR‐SSP) in a low‐resolution typing method was carried out on blood samples collected for HLA‐DQ and ‐DR allele typing.Results: The cases and controls had comparable mean ages (31 vs. 32 years), and most cases were female (95.1% vs. 34.4%). The most frequent clinical manifestations were mucocutaneous (85.4%), followed by musculoskeletal (70.7%) and constitutional symptoms (58.5%). The cases had a significantly higher frequency of HLA‐DR2 allele compared with healthy controls (70.7% vs. 43.8%; odds ratio: 3.1; 95% confidence interval: 1.2–8.2). In addition, HLA‐DQ6 allele was found to have a significant association with mucocutaneous manifestations of the cases (88.9%, P = 0.03).Conclusions: Bangladeshi adults having HLA‐DR2 may be more susceptible to SLE. HLA‐DQ6 allele might be associated with mucocutaneous manifestations of SLE.
- 24 February 2023
- Published by Wiley in Rheumatology & Autoimmunity
- Vol. 3 (1) , 43-49
Open AccessHLA‐DQ and ‐DR alleles in patients with SLE: A tertiary hospital‐based case–control study in Bangladesh
Background: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the involvement of multiple organs and autoantibody production. This study aimed to determine the association of human leukocyte antigen (HLA)‐DQ and ‐DR alleles with SLE at a tertiary hospital in Bangladesh.Methods: This case–control study was conducted in the Department of Rheumatology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh. The patients who fulfilled the 1997 revised American College of Rheumatology classification criteria for SLE were considered cases (n = 41). The controls (n = 32) were selected from the hospital staff of BSMMU, including doctors and nurses who did not suffer from any known rheumatic diseases, and there was no such disease in their first‐degree relatives. Polymerase chain reaction using a sequence‐specific primer (PCR‐SSP) in a low‐resolution typing method was carried out on blood samples collected for HLA‐DQ and ‐DR allele typing.Results: The cases and controls had comparable mean ages (31 vs. 32 years), and most cases were female (95.1% vs. 34.4%). The most frequent clinical manifestations were mucocutaneous (85.4%), followed by musculoskeletal (70.7%) and constitutional symptoms (58.5%). The cases had a significantly higher frequency of HLA‐DR2 allele compared with healthy controls (70.7% vs. 43.8%; odds ratio: 3.1; 95% confidence interval: 1.2–8.2). In addition, HLA‐DQ6 allele was found to have a significant association with mucocutaneous manifestations of the cases (88.9%, P = 0.03).Conclusions: Bangladeshi adults having HLA‐DR2 may be more susceptible to SLE. HLA‐DQ6 allele might be associated with mucocutaneous manifestations of SLE.
- Open Access
- 21 September 2022
- Published by Wiley in Rheumatology & Autoimmunity
- Vol. 2 (3) , 141-149
Associations of autoantibodies and clinical profile of the patients with systemic sclerosis
Background: Systemic sclerosis is characterized by the involvement of organs and the presence of specific antibodies. The objectives of this study were to identify the autoantibodies and to determine their association with the selected clinical features of the disease among Bangladeshi systemic sclerosis patients.Methods: This cross‐sectional study was performed at the rheumatology outpatient clinic of Bangabandhu Sheikh Mujib Medical University. Autoantibodies against nine systemic sclerosis‐specific antigens were tested using an enzyme‐linked immunoassay immunoblot kit. Several clinical features of patients with positive and negative autoantibody were examined by χ2 or Fisher's exact tests.Results: A total of 71 patients with systemic sclerosis (66; 93.0% female) were included. Their mean age at disease onset was 33.2 years. Fifty‐seven (80.3%) patients had diffuse cutaneous subtype. Out of nine autoantibodies, four were positive, anti‐topoisomerase‐I (57.7%), anti‐U1 ribonucleic protein (21.1%), anti‐RNA polymerase III (18.3%), and anticentromere antibodies (4.2%). Eleven (15.5%) patients were negative for any antibodies and 11 patients were positive for at least two autoantibodies. Anti‐U3‐RNP, anti‐PM‐Scl, anti‐Ku, and anti‐Th/To auto antibodies were absent in all patients. Anti‐RNA polymerase III was associated with raised pulmonary arterial systolic pressure (PASP) and anti‐U1‐RNP with decreased forced vital capacity (FVC).Conclusions: Anti‐topoisomerase‐I was the commonest autoantibody in patients with systemic sclerosis in Bangladesh. Anti‐RNA polymerase III antibody had significant association with raised PASP and anti‐U1‐RNP with decreased FVC.
- 21 September 2022
- Published by Wiley in Rheumatology & Autoimmunity
- Vol. 2 (3) , 141-149
Open AccessAssociations of autoantibodies and clinical profile of the patients with systemic sclerosis
Background: Systemic sclerosis is characterized by the involvement of organs and the presence of specific antibodies. The objectives of this study were to identify the autoantibodies and to determine their association with the selected clinical features of the disease among Bangladeshi systemic sclerosis patients.Methods: This cross‐sectional study was performed at the rheumatology outpatient clinic of Bangabandhu Sheikh Mujib Medical University. Autoantibodies against nine systemic sclerosis‐specific antigens were tested using an enzyme‐linked immunoassay immunoblot kit. Several clinical features of patients with positive and negative autoantibody were examined by χ2 or Fisher's exact tests.Results: A total of 71 patients with systemic sclerosis (66; 93.0% female) were included. Their mean age at disease onset was 33.2 years. Fifty‐seven (80.3%) patients had diffuse cutaneous subtype. Out of nine autoantibodies, four were positive, anti‐topoisomerase‐I (57.7%), anti‐U1 ribonucleic protein (21.1%), anti‐RNA polymerase III (18.3%), and anticentromere antibodies (4.2%). Eleven (15.5%) patients were negative for any antibodies and 11 patients were positive for at least two autoantibodies. Anti‐U3‐RNP, anti‐PM‐Scl, anti‐Ku, and anti‐Th/To auto antibodies were absent in all patients. Anti‐RNA polymerase III was associated with raised pulmonary arterial systolic pressure (PASP) and anti‐U1‐RNP with decreased forced vital capacity (FVC).Conclusions: Anti‐topoisomerase‐I was the commonest autoantibody in patients with systemic sclerosis in Bangladesh. Anti‐RNA polymerase III antibody had significant association with raised PASP and anti‐U1‐RNP with decreased FVC.
- Open Access
- 25 July 2022
- Published by Oxford University Press (OUP) in Health Policy and Planning
- Vol. 38 (2) , 129-149
Context and priorities for health systems strengthening for pain and disability in low- and middle-income countries: a secondary qualitative study and content analysis of health policies
Musculoskeletal (MSK) health impairments contribute substantially to the pain and disability burden in low- and middle-income countries (LMICs), yet health systems strengthening (HSS) responses are nascent in these settings. We aimed to explore the contemporary context, framed as challenges and opportunities, for improving population-level prevention and management of MSK health in LMICs using secondary qualitative data from a previous study exploring HSS priorities for MSK health globally and (2) to contextualize these findings through a primary analysis of health policies for integrated management of non-communicable diseases (NCDs) in select LMICs. Part 1: 12 transcripts of interviews with LMIC-based key informants (KIs) were inductively analysed. Part 2: systematic content analysis of health policies for integrated care of NCDs where KIs were resident (Argentina, Bangladesh, Brazil, Ethiopia, India, Kenya, Malaysia, Philippines and South Africa). A thematic framework of LMIC-relevant challenges and opportunities was empirically derived and organized around five meta-themes: (1) MSK health is a low priority; (2) social determinants adversely affect MSK health; (3) healthcare system issues de-prioritize MSK health; (4) economic constraints restrict system capacity to direct and mobilize resources to MSK health; and (5) build research capacity. Twelve policy documents were included, describing explicit foci on cardiovascular disease (100%), diabetes (100%), respiratory conditions (100%) and cancer (89%); none explicitly focused on MSK health. Policy strategies were coded into three categories: (1) general principles for people-centred NCD care, (2) service delivery and (3) system strengthening. Four policies described strategies to address MSK health in some way, mostly related to injury care. Priorities and opportunities for HSS for MSK health identified by KIs aligned with broader strategies targeting NCDs identified in the policies. MSK health is not currently prioritized in NCD health policies among selected LMICs. However, opportunities to address the MSK-attributed disability burden exist through integrating MSK-specific HSS initiatives with initiatives targeting NCDs generally and injury and trauma care.
- 25 July 2022
- Published by Oxford University Press (OUP) in Health Policy and Planning
- Vol. 38 (2) , 129-149
Open AccessContext and priorities for health systems strengthening for pain and disability in low- and middle-income countries: a secondary qualitative study and content analysis of health policies
Musculoskeletal (MSK) health impairments contribute substantially to the pain and disability burden in low- and middle-income countries (LMICs), yet health systems strengthening (HSS) responses are nascent in these settings. We aimed to explore the contemporary context, framed as challenges and opportunities, for improving population-level prevention and management of MSK health in LMICs using secondary qualitative data from a previous study exploring HSS priorities for MSK health globally and (2) to contextualize these findings through a primary analysis of health policies for integrated management of non-communicable diseases (NCDs) in select LMICs. Part 1: 12 transcripts of interviews with LMIC-based key informants (KIs) were inductively analysed. Part 2: systematic content analysis of health policies for integrated care of NCDs where KIs were resident (Argentina, Bangladesh, Brazil, Ethiopia, India, Kenya, Malaysia, Philippines and South Africa). A thematic framework of LMIC-relevant challenges and opportunities was empirically derived and organized around five meta-themes: (1) MSK health is a low priority; (2) social determinants adversely affect MSK health; (3) healthcare system issues de-prioritize MSK health; (4) economic constraints restrict system capacity to direct and mobilize resources to MSK health; and (5) build research capacity. Twelve policy documents were included, describing explicit foci on cardiovascular disease (100%), diabetes (100%), respiratory conditions (100%) and cancer (89%); none explicitly focused on MSK health. Policy strategies were coded into three categories: (1) general principles for people-centred NCD care, (2) service delivery and (3) system strengthening. Four policies described strategies to address MSK health in some way, mostly related to injury care. Priorities and opportunities for HSS for MSK health identified by KIs aligned with broader strategies targeting NCDs identified in the policies. MSK health is not currently prioritized in NCD health policies among selected LMICs. However, opportunities to address the MSK-attributed disability burden exist through integrating MSK-specific HSS initiatives with initiatives targeting NCDs generally and injury and trauma care.
- Open Access
- 8 April 2022
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 23 (1) , 1-9
Risk factors of knee osteoarthritis in Bangladeshi adults: a national survey
Background: Knee osteoarthritis was reported as the second most prevalent condition in the national musculoskeletal survey. The purpose of this extended study was to identify risk factors for knee osteoarthritis in Bangladeshi adults. Methods: This cross-sectional study was conducted in rural and urban areas of Bangladesh using stratified multistage cluster sample of 2000 adults aged 18 years or older recruited at their households. The Modified Community Oriented Program for Control of Rheumatic Disorders (COPCORD) questionnaire was used to collect data. The diagnosis of knee osteoarthritis was made using the decision tree clinical categorization criteria of the American College of Rheumatology. Univariate and multivariate logistic regression analyses were done to identify the risk factors for knee osteoarthritis. Results: A total of 1843 individuals (892 men and 951 women) participated, and 134 had knee osteoarthritis yielding a prevalence of 7.3% (95% confidence interval (CI) 4.9 to 9.6%). The mean (standard deviation) age of the knee osteoarthritis patients was 51.7 (11.2) years. Multivariate logistic regression analysis found a significant association with increasing age (≥38 years OR 8.9, 95% CI 4.8–16.5; ≥58 years OR 13.9, 95% CI 6.9–28.0), low educational level (OR 1.7, 95% CI 1.0–2.7) and overweight (OR 1.9, 95% CI 1.2–2.9) with knee osteoarthritis. Knee osteoarthritis patients had a high likelihood of having work loss preceding 12 months (age and sex-adjusted OR 2.3; 95% CI 1.4–3.8; P < 0.01). Conclusions: Knee osteoarthritis is a commonly prevalent musculoskeletal problem among Bangladeshi adults having link to work loss. Increasing age, low education and overweight are significant risk factors of knee osteoarthritis.
- 8 April 2022
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 23 (1) , 1-9
Open AccessRisk factors of knee osteoarthritis in Bangladeshi adults: a national survey
Background: Knee osteoarthritis was reported as the second most prevalent condition in the national musculoskeletal survey. The purpose of this extended study was to identify risk factors for knee osteoarthritis in Bangladeshi adults. Methods: This cross-sectional study was conducted in rural and urban areas of Bangladesh using stratified multistage cluster sample of 2000 adults aged 18 years or older recruited at their households. The Modified Community Oriented Program for Control of Rheumatic Disorders (COPCORD) questionnaire was used to collect data. The diagnosis of knee osteoarthritis was made using the decision tree clinical categorization criteria of the American College of Rheumatology. Univariate and multivariate logistic regression analyses were done to identify the risk factors for knee osteoarthritis. Results: A total of 1843 individuals (892 men and 951 women) participated, and 134 had knee osteoarthritis yielding a prevalence of 7.3% (95% confidence interval (CI) 4.9 to 9.6%). The mean (standard deviation) age of the knee osteoarthritis patients was 51.7 (11.2) years. Multivariate logistic regression analysis found a significant association with increasing age (≥38 years OR 8.9, 95% CI 4.8–16.5; ≥58 years OR 13.9, 95% CI 6.9–28.0), low educational level (OR 1.7, 95% CI 1.0–2.7) and overweight (OR 1.9, 95% CI 1.2–2.9) with knee osteoarthritis. Knee osteoarthritis patients had a high likelihood of having work loss preceding 12 months (age and sex-adjusted OR 2.3; 95% CI 1.4–3.8; P < 0.01). Conclusions: Knee osteoarthritis is a commonly prevalent musculoskeletal problem among Bangladeshi adults having link to work loss. Increasing age, low education and overweight are significant risk factors of knee osteoarthritis.
- 8 March 2022
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 56 (3) , 158-168
Relationship Between Vitamin D Status and Brain Perfusion in Neuropsychiatric Lupus
Purpose Neuropsychiatric manifestation of lupus (NPSLE) is related with vitamin D (vit-D) deficiency which is possibly amenable to supplementation. This study was done to explore link of serum vit-D level and clinical mini-mental state examination (MMSE) with brain perfusion SPECT (BS) in patients with NPSLE. Methods Patients who underwent BS with the diagnosis of NPSLE and had serum levels of vit-D and MMSE within a span of 1 month were retrospectively included. The BS DICOM data were used to generate 3D surface images of brain for visual identification of regional hypoperfusion, and the z-scores from eZIS software and then to perform voxel-based regression analysis in order to explore association between serum vit-D level and cerebral perfusion deficit using SPM8. Distribution of serum vit-D level was checked across MMSE and BS z-score using R. Results A total 19 patients with means ± SD age of 28.4 ± 9.2 years, having mean levels of serum vit-D of 18.7 ± 9.8 ng/ml and mean MMSE scores 24.2 ± 1.6, had undergone BS. The eZIS-derived z-score fall in the category of normal in six (31.6%), mild perfusion deficit (PD) in 10 (52.6%) and moderate PD in three (15.8%) with the means ± SD of z-score being 0.52 ± 0.2, 1.72 ± 0.2, and 2.33 ± 0.2. Voxel-based analysis revealed significant positive correlation between vit-D level and hypoperfusion in brain regions related to cognitive function (pz-score (p < 0.01). Conclusions Our results may support the utility of vit-D supplementation in NPSLE and applicability of BS as a clinical adjunct for monitoring response to vit-D supplementation.
- 8 March 2022
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 56 (3) , 158-168
Relationship Between Vitamin D Status and Brain Perfusion in Neuropsychiatric Lupus
Purpose Neuropsychiatric manifestation of lupus (NPSLE) is related with vitamin D (vit-D) deficiency which is possibly amenable to supplementation. This study was done to explore link of serum vit-D level and clinical mini-mental state examination (MMSE) with brain perfusion SPECT (BS) in patients with NPSLE. Methods Patients who underwent BS with the diagnosis of NPSLE and had serum levels of vit-D and MMSE within a span of 1 month were retrospectively included. The BS DICOM data were used to generate 3D surface images of brain for visual identification of regional hypoperfusion, and the z-scores from eZIS software and then to perform voxel-based regression analysis in order to explore association between serum vit-D level and cerebral perfusion deficit using SPM8. Distribution of serum vit-D level was checked across MMSE and BS z-score using R. Results A total 19 patients with means ± SD age of 28.4 ± 9.2 years, having mean levels of serum vit-D of 18.7 ± 9.8 ng/ml and mean MMSE scores 24.2 ± 1.6, had undergone BS. The eZIS-derived z-score fall in the category of normal in six (31.6%), mild perfusion deficit (PD) in 10 (52.6%) and moderate PD in three (15.8%) with the means ± SD of z-score being 0.52 ± 0.2, 1.72 ± 0.2, and 2.33 ± 0.2. Voxel-based analysis revealed significant positive correlation between vit-D level and hypoperfusion in brain regions related to cognitive function (pz-score (p < 0.01). Conclusions Our results may support the utility of vit-D supplementation in NPSLE and applicability of BS as a clinical adjunct for monitoring response to vit-D supplementation.